Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Eur J Pharmacol ; 962: 176202, 2024 Jan 05.
Artículo en Inglés | MEDLINE | ID: mdl-37996010

RESUMEN

Phosphodiesterase 4 (PDE4) inhibitors are expected to exhibit efficacy against inflammatory diseases due to their broad pharmacological activity. The launched PDE4 inhibitors apremilast, crisaborole, and roflumilast have not exhibited sufficient inhibitory potential due to poor margins of effectiveness and tolerability. In this report, we describe the non-clinical efficacy, brain translocation, and vomit-inducing effects of ME3183 compared with apremilast. ME3183 showed extensive cytokine suppression in vitro studies using human peripheral blood mononuclear cells and T cells. ME3183 also significantly suppressed skin inflammation in a chronic oxazolone-induced dermatitis model and showed antipruritic effects in a substance P-induced mouse pruritus model. In these in vitro and in vivo studies, ME3183 also significantly suppressed cytokines, and focusing on tumor necrosis factor-α as a psoriasis-related cytokine and interleukin-4 as an atopic dermatitis-related cytokine, ME3183 potently inhibited both cytokines. ME3183 showed in vivo efficacy at lower doses than apremilast. The brain distribution of ME3183 was sufficiently low in mice and rats. The effective dose of ME3183 for emesis was similar to that of apremilast in ferrets. Given its high-potency inhibitory effects, ME3183 would have a wide margin of efficacy and tolerability. These wide margins demonstrate the effectiveness of ME3183 in treating many inflammatory diseases, such as psoriasis and atopic dermatitis. An on-going phase 2 trial is expected to further demonstrate the efficacy and safety of ME3183.


Asunto(s)
Dermatitis Atópica , Inhibidores de Fosfodiesterasa 4 , Psoriasis , Animales , Ratones , Humanos , Ratas , Inhibidores de Fosfodiesterasa 4/farmacología , Inhibidores de Fosfodiesterasa 4/uso terapéutico , Dermatitis Atópica/tratamiento farmacológico , Fosfodiesterasas de Nucleótidos Cíclicos Tipo 4 , Leucocitos Mononucleares , Hurones , Psoriasis/patología , Citocinas , Inflamación/tratamiento farmacológico , Antiinflamatorios/uso terapéutico
2.
ChemistryOpen ; 10(3): 352-359, 2021 03.
Artículo en Inglés | MEDLINE | ID: mdl-33605559

RESUMEN

Porous polyimide (PI) membranes are widely used in separation processes because of their excellent thermal and mechanical properties. However, the applications of porous PI membranes are limited in the nanofiltration range. In this study, porous PI membranes with through-holes have been successfully fabricated by the novel multiple solvent displacement method. This new method requires only a porous polyamic acid (PAA) membrane, which was prepared by immersing PAA film in N-methylpyrrolidoneebk; (NMP) prior to immersing it in a mixed solvent consisting of NMP and a poor solvent, followed by immersion only in poor solvent. The pore size, morphology, porosity, and air permeability demonstrated that the fabricated PI membranes had a uniformly porous structure with through-holes over their surface. This new method enabled control of pore size (3-11 µm) by selecting a suitable poor solvent. This multiple solvent displacement method is highly versatile and promising for the fabrication of porous PI membranes.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...